Recurrent giant cellulitis-like Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Penelope Hirt; Lily Park; Carly E Wallace; Francisco Kerdel

doi:10.4081/dr.2023.9668

Recurrent giant cellulitis-like Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine

Dermatol Reports. 2023 May 23;15(3):9668. doi: 10.4081/dr.2023.9668. eCollection 2023 Sep 12.

Authors

Penelope Hirt¹, Lily Park¹, Carly E Wallace², Francisco Kerdel³

Affiliations

¹ Department of Dermatology, Larkin Community Hospital, Miami, FL.
² Lake Erie College of Osteopathic Medicine, Bradenton, FL.
³ Florida Academic Dermatology Center, Miami, FL, USA.

Abstract

Primary and booster vaccines for SARS-CoV-2 are the most effective methods of preventing infection and are generally considered safe. However, many cutaneous adverse events have been reported following vaccination. To date, there have been seven reported cases of Sweet syndrome occurring after the first dose of the SARS-CoV-2 vaccine. We describe a rare case of atypical giant-cellulitis like Sweet syndrome reemerging after receiving the SARS-CoV-2 booster vaccine.

Keywords: COVID-19; SARS-CoV-2; sweet syndrome; vaccine.

Grants and funding

Funding: this research received no external source of funding.